Deucrictibant

Deucrictibant
Clinical data
Other namesPHA-022121; PHA-121; PHVS 416; PHVS 719; PHVS416; PHVS719
Legal status
Legal status
  • investigational
Identifiers
  • N-[(1S)-1-[3-chloro-5-fluoro-2-[[2-methyl-4-(2-methyl-1,2,4-triazol-3-yl)quinolin-8-yl]oxymethyl]phenyl]-1-deuterioethyl]-2-(difluoromethoxy)acetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC25H23ClF3N5O3
Molar mass533.94 g·mol−1
3D model (JSmol)
  • [2H][C@](C)(C1=C(C(=CC(=C1)F)Cl)COC2=CC=CC3=C(C=C(N=C32)C)C4=NC=NN4C)NC(=O)COC(F)F
  • InChI=InChI=1S/C25H23ClF3N5O3/c1-13-7-18(24-30-12-31-34(24)3)16-5-4-6-21(23(16)32-13)36-10-19-17(8-15(27)9-20(19)26)14(2)33-22(35)11-37-25(28)29/h4-9,12,14,25H,10-11H2,1-3H3,(H,33,35)/t14-/m0/s1/i14D
  • Key:ZTCLCSCHTACERP-WTDRUJNCSA-N

Deucrictibant is an investigational new drug that is being evaluated by Pharvaris for the treatment of hereditary angioedema (HAE). It is a bradykinin receptor B2 antagonist which blocks bradykinin-driven swelling attacks which is a characteristic of HAE.

Deucrictibant contains a deuterium atom to stabilize it against metabolism and to prolong the half-life of the drug.

Clinical trials

Deucrictibant is in phase 3 clinical trials for hereditary angioedema.

References

  1. ↑ "Deucrictibant - Pharvaris". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Sahli A, C-Gaudreault R, Marceau F (January 2026). "Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: Pharmacological properties and prospective clinical uses". Peptides. 195 171466. doi:10.1016/j.peptides.2026.171466. PMID 41548609.
  3. ↑ Busse PJ, Fok JS, Kamdar SS, Longhurst HJ, Riedl MA (February 2026). "Updates on the Current and Evolving Treatment for Hereditary Angioedema". The Journal of Allergy and Clinical Immunology. In Practice. 14 (2): 375–383. doi:10.1016/j.jaip.2025.11.039. PMID 41654335.
  4. ↑ Maurer M, Lesage A, Crabbé R, Lu P, Groen K, Rodriguez M, et al. (2023). "The EC85 derived from the oral bradykinin B2 receptor antagonist deucrictibant (PHA121) against bradykinin effects in healthy volunteers predicts the onset and duration of its clinical effects in hereditary angioedema". Allergy, Asthma & Clinical Immunology. 19 (Suppl 1): 106. doi:10.1186/s13223-023-00845-9. PMC 10731679. PMID 38124188. Presented at: 13th C1-Inhibitor Deficiency and Angioedema Workshop; 2023 May 4–7; Budapest, Hungary.
  5. ↑ Clinical trial number NCT06669754 for "Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE" at ClinicalTrials.gov